AbbVie stock tumbles 11% on disappointing results for cancer drug acquired in $5.8 billion deal
March 22, 2018 at 10:05 AM EDT
Investors were hoping for accelerated approval so the drug could quickly begin bringing in revenue. But the new trial results also undermine the core reasons AbbVie bought Stemcentrx and Rova-T in the first place.
